Based on the key measurements obtained from Biomerica's financial statements, Biomerica may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Biomerica's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Net Receivables is expected to grow to about 950.1 K, whereas Total Assets are forecasted to decline to about 7.4 M. Key indicators impacting Biomerica's financial strength include:
Investors should never underestimate Biomerica's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Biomerica's cash flow, debt, and profitability to make informed and accurate decisions about investing in Biomerica.
Net Income
(5.68 Million)
Biomerica
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Net Income
End Period Cash Flow
Total Cash From Financing Activities
Other Non Cash Items
Change To Liabilities
Total Cashflows From Investing Activities
Change To Account Receivables
Other Cashflows From Investing Activities
Sale Purchase Of Stock
Stock Based Compensation
Change Receivables
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Operating Activities
Change To Netincome
Investments
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Accounts Payable
Short Long Term Debt Total
Short Term Debt
Intangible Assets
Common Stock Total Equity
Common Stock
Other Assets
Property Plant Equipment
Current Deferred Revenue
Retained Earnings Total Equity
Net Tangible Assets
Capital Surpluse
Accumulated Depreciation
Deferred Long Term Asset Charges
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Research Development
Minority Interest
Net Income Applicable To Common Shares
Net Income From Continuing Ops
Non Operating Income Net Other
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Biomerica Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biomerica's financial statements are interrelated, with each one affecting the others. For example, an increase in Biomerica's assets may result in an increase in income on the income statement.
Please note, the presentation of Biomerica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomerica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomerica's management manipulating its earnings.
Biomerica Stock Summary
Biomerica competes with SurModics, Movano, Ainos, Tivic Health, and Bone Biologics. Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection andor treatment of medical conditions and diseases worldwide. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Biomerica operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.
Comparative valuation techniques use various fundamental indicators to help in determining Biomerica's current stock value. Our valuation model uses many indicators to compare Biomerica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomerica competition to find correlations between indicators driving Biomerica's intrinsic value. More Info.
Biomerica is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Biomerica's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biomerica's earnings, one of the primary drivers of an investment's value.
Biomerica Systematic Risk
Biomerica's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biomerica volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Biomerica correlated with the market. If Beta is less than 0 Biomerica generally moves in the opposite direction as compared to the market. If Biomerica Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biomerica is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biomerica is generally in the same direction as the market. If Beta > 1 Biomerica moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Biomerica Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomerica's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biomerica growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0554
At present, Biomerica's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Biomerica November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biomerica help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biomerica. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biomerica based on widely used predictive technical indicators. In general, we focus on analyzing Biomerica Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biomerica's daily price indicators and compare them against related drivers.
When running Biomerica's price analysis, check to measure Biomerica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomerica is operating at the current time. Most of Biomerica's value examination focuses on studying past and present price action to predict the probability of Biomerica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomerica's price. Additionally, you may evaluate how the addition of Biomerica to your portfolios can decrease your overall portfolio volatility.